The interim data from the Akeso Bio run HARMONi-6 trial were first presented by Dr Shun Lu at ESMO last year.

Chicago!

Tired of all the Wall St platitudes and too much hand waving, we posted a detailed critique of the data here where the underlying issues were explored and explained in the context of what we knew at the time.

It even included an unexpected mic drop moment from the discussant (Dr Myung-Ju Ahn, S Korea).

There was also a prediction about the chances of repeat success for the global HARMONi-3 study run by Summit Therapeutics.

Fast forward eight months and the same trial with more mature data was presented in the plenary session at ASCO in Chicago earlier today.

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers